Therefore, the current study was designed to compare the treatment response, survival benefit, and safety profile of PD-1 inhibitor plus apatinib versus apatinib monotherapy as third-line therapies in advanced CRC patients. Here, PDCD1 is linked to colorectal carcinoma.